Frances F Hamilton
Examiner (ID: 6060, Phone: (571)270-5726 , Office: P/3749 )
Most Active Art Unit | 3749 |
Art Unit(s) | 3762, 3749, 3743 |
Total Applications | 712 |
Issued Applications | 361 |
Pending Applications | 48 |
Abandoned Applications | 303 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18739642
[patent_doc_number] => 20230348604
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/309272
[patent_app_country] => US
[patent_app_date] => 2023-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18309272
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/309272 | ANTIGEN BINDING PROTEINS | Apr 27, 2023 | Pending |
Array
(
[id] => 17990221
[patent_doc_number] => 20220356258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => Method for Producing Spesolimab
[patent_app_type] => utility
[patent_app_number] => 17/734417
[patent_app_country] => US
[patent_app_date] => 2022-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17531
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734417
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/734417 | Method for Producing Spesolimab | May 1, 2022 | Pending |
Array
(
[id] => 17960354
[patent_doc_number] => 20220340934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => METHOD FOR SINGLE-BASE GENOME EDITING USING CRISPR/CPF1 SYSTEM AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/727142
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727142
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/727142 | METHOD FOR SINGLE-BASE GENOME EDITING USING CRISPR/CPF1 SYSTEM AND USES THEREOF | Apr 21, 2022 | Pending |
Array
(
[id] => 17657134
[patent_doc_number] => 20220177599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1
[patent_app_type] => utility
[patent_app_number] => 17/457785
[patent_app_country] => US
[patent_app_date] => 2021-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17457785
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/457785 | DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1 | Dec 5, 2021 | Pending |
Array
(
[id] => 17036719
[patent_doc_number] => 20210253677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => AGROCHEMICAL COMPOSITIONS COMPRISING ANTIBODIES BINDING TO SPHINGOLIPIDS
[patent_app_type] => utility
[patent_app_number] => 17/150147
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150147
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150147 | AGROCHEMICAL COMPOSITIONS COMPRISING ANTIBODIES BINDING TO SPHINGOLIPIDS | Jan 14, 2021 | Pending |
Array
(
[id] => 16977603
[patent_doc_number] => 20210221840
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR VIRAL CLEARANCE
[patent_app_type] => utility
[patent_app_number] => 17/150973
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150973
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150973 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR VIRAL CLEARANCE | Jan 14, 2021 | Pending |
Array
(
[id] => 16807898
[patent_doc_number] => 20210130451
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => TREATMENT FOR RHEUMATOID ARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 17/144685
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144685
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/144685 | TREATMENT FOR RHEUMATOID ARTHRITIS | Jan 7, 2021 | Pending |
Array
(
[id] => 17228670
[patent_doc_number] => 20210355226
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => IL3Ralpha Antibody Conjugates and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/132726
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17132726
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/132726 | IL3Ralpha Antibody Conjugates and Uses Thereof | Dec 22, 2020 | Pending |
Array
(
[id] => 16822690
[patent_doc_number] => 20210137983
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => NK CELL EXPANSION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/091741
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091741
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/091741 | NK CELL EXPANSION AND USES THEREOF | Nov 5, 2020 | Pending |
Array
(
[id] => 16749973
[patent_doc_number] => 20210101982
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/061998
[patent_app_country] => US
[patent_app_date] => 2020-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27483
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -130
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061998
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/061998 | ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Oct 1, 2020 | Pending |
Array
(
[id] => 17733350
[patent_doc_number] => 20220218809
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => IDO ACTIVITY AS A MARKER OF TUMOR IMMUNE ESCAPE AND IDO INHIBITORS AS A MEANS OF ENHANCING T CELLS RESPONSE TO ANTIGEN SPECIFIC VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/291159
[patent_app_country] => US
[patent_app_date] => 2019-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10396
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291159
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/291159 | IDO ACTIVITY AS A MARKER OF TUMOR IMMUNE ESCAPE AND IDO INHIBITORS AS A MEANS OF ENHANCING T CELLS RESPONSE TO ANTIGEN SPECIFIC VACCINE | Nov 5, 2019 | Pending |
Array
(
[id] => 17228667
[patent_doc_number] => 20210355223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => Combinations for Treating Cancer
[patent_app_type] => utility
[patent_app_number] => 17/291069
[patent_app_country] => US
[patent_app_date] => 2019-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291069
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/291069 | Combinations for Treating Cancer | Nov 3, 2019 | Pending |
Array
(
[id] => 17595353
[patent_doc_number] => 20220144926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => IDENTIFICATION AND TARGETING OF PATHOGENIC EXTRACELLULAR MATRIX FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/286206
[patent_app_country] => US
[patent_app_date] => 2019-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286206
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/286206 | IDENTIFICATION AND TARGETING OF PATHOGENIC EXTRACELLULAR MATRIX FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES | Oct 15, 2019 | Pending |
Array
(
[id] => 17595368
[patent_doc_number] => 20220144941
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS
[patent_app_type] => utility
[patent_app_number] => 17/286247
[patent_app_country] => US
[patent_app_date] => 2019-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286247
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/286247 | METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS | Oct 15, 2019 | Pending |
Array
(
[id] => 17336107
[patent_doc_number] => 20220002438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => MUSK INHIBITION
[patent_app_type] => utility
[patent_app_number] => 17/272791
[patent_app_country] => US
[patent_app_date] => 2019-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33747
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272791
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/272791 | MUSK INHIBITION | Sep 4, 2019 | Pending |
Array
(
[id] => 17141700
[patent_doc_number] => 20210309712
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => CAR-EXPRESSING T CELLS AND CAR EXPRESSION VECTOR
[patent_app_type] => utility
[patent_app_number] => 17/271451
[patent_app_country] => US
[patent_app_date] => 2019-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20206
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271451
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/271451 | CAR-EXPRESSING T CELLS AND CAR EXPRESSION VECTOR | Aug 29, 2019 | Pending |
Array
(
[id] => 17141730
[patent_doc_number] => 20210309742
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/264702
[patent_app_country] => US
[patent_app_date] => 2019-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29727
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264702
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/264702 | CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY | Aug 19, 2019 | Pending |
Array
(
[id] => 16870426
[patent_doc_number] => 20210163893
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/267000
[patent_app_country] => US
[patent_app_date] => 2019-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 183341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -208
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267000
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/267000 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | Aug 8, 2019 | Pending |
Array
(
[id] => 17126253
[patent_doc_number] => 20210301021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => HUMANIZED ANTI-HUMAN CTLA4 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/263148
[patent_app_country] => US
[patent_app_date] => 2019-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17263148
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/263148 | HUMANIZED ANTI-HUMAN CTLA4 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF | Jul 24, 2019 | Pending |
Array
(
[id] => 16808224
[patent_doc_number] => 20210130777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => METHOD FOR PRODUCING GAMMA DELTA T CELLS
[patent_app_type] => utility
[patent_app_number] => 17/259736
[patent_app_country] => US
[patent_app_date] => 2019-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16696
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259736
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/259736 | METHOD FOR PRODUCING GAMMA DELTA T CELLS | Jul 11, 2019 | Pending |